Virax Biolabs (VRAX) Invested Capital (2023 - 2026)

Virax Biolabs' Invested Capital history runs 3 years deep, the most recent figure standing at $28477.0 for Q1 2026.

• In Q1 2026, Invested Capital fell 12.29% year-over-year to $28477.0; the TTM figure through Mar 2026 stood at $60945.0 (down 65.9% YoY), while the FY2026 annual figure was $28477.0, down 12.29% from the prior year.
• Invested Capital for Q1 2026 stood at $28477.0, down from $32468.0 in the prior quarter.
• The five-year high for Invested Capital was $146250.0 in Q1 2023, with the low at $28477.0 in Q1 2026.
• The 3-year median for Invested Capital is $32468.0 (2025), against an average of $69065.0.
• Peak annual rise in Invested Capital reached 12.29% in 2026, while the deepest fall reached 12.29% in 2026.
• Virax Biolabs' Invested Capital stood at $146250.0 in 2023, then sank by 77.8% to $32468.0 in 2025, then decreased by 12.29% to $28477.0 in 2026.
• Business Quant data shows VRAX's Invested Capital at $28477.0 in Q1 2026, $32468.0 in Q1 2025, and $146250.0 in Q1 2023.